Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
5Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Aardvark Therapeutics, Inc. (AARD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
2Distinct source URLs
4High confidence
0.782Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Aardvark Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
PIPER-SANDLER-CO
PIPER-SANDLER-CO
90%
The Company has agreed in the Equity Distribution Agreement to provide indemnification and contribution to the Agent against certain liabilities, including liabilities under the Securities Act of 193…
Reciprocal relationship from SCLX graph: ement with EAR SPV LLC, a Delaware corporation (“EAR SPV”) and Vivasor Holding Company (“VHC”), a privately held biotechnology company, pursuant to which, amo…
Reciprocal relationship from DRUG graph: Reciprocal relationship from AARD graph: Reciprocal relationship from DRUG graph: Reciprocal relationship from AARD graph: Reciprocal relationship from DRUG g…
, operating results, prospects or financial condition. Risks Related to Artificial Intelligence We may use certain artificial intelligence (AI) technologies, which present risks and challenges that c…
, operating results, prospects or financial condition. Risks Related to Artificial Intelligence We may use certain artificial intelligence (AI) technologies, which present risks and challenges that c…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
sts due to increased headcount and bonuses. General and Administrative (G&A) Expenses G&A expenses were $5.9 million and $2.7 million for the three months ended March 31, 2026 and 2025, respectively.…
Aardvark Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
AARD-DEBT
Debt stack $336,000
90%
Market cache reports total debt of $336,000.
AARD-DEBT-7408
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Aardvark Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Aardvark Therapeutics, Inc..
Aardvark Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
AARD-OWNER-DECHENG-CAPITAL-LLC
Decheng Capital LLC
90%
13F overlay lists Decheng Capital LLC as top holder; 80 tracked holders.
Aardvark Therapeutics, Inc. Extended Supply Chain Network
